Another subgroup was enriched for patients with myelofibrosis (odds ratio, 6.5; 95% CI, 4.9–8.7; P < 0.001) and it was defined by LOH at chromosome 4q, aberrations in chromosomes 7 and 7q occurring together with mutations in at least 14 myeloid cancer genes (EZH2, IDH1, IDH2, ASXL1, PHF6, CUX1, ZRSR2, SRSF2, U2AF1, KRAS, NRAS, GNAS, CBL, Chr7/7qLOH, Chr4qLOH, RUNX1, STAG2 and BCOR), accounting for the biggest co-mutation pattern in the Bayesian network. The gene discussed is SRSF2; the disease is myelofibrosis.